BACKGROUND: Dosimetry can tailor prostate-specific membrane-antigen-targeted radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However, whole-body tumor dosimetry is challenging in patients with a high tumor burden. We evaluate a simplified index-lesion-based single-photon emission computed tomography (SPECT) dosimetry method in correlation with clinical outcome. METHODS: 30 mCRPC patients were included (median 71 years). The dosimetry was performed for the first cycle using quantitative 177Lu-SPECT. The response was evaluated using RECIST 1.1 and PERCIST criteria, as well as changes in PSMA-positive tumor volume (PSMA-TV) in post-therapy PSMA-PET and biochemical response according to PSA changes after two RLT cycles. RESULTS: Mean tumor doses as well as index-lesion doses were significantly higher in PERCIST responders compared to non-responders (10.2 ± 12.0 Gy/GBq vs. 4.0 ± 2.9 Gy/GBq, p = 0.03 and 13.7 ± 14.2 Gy/GBq vs. 5.9 ± 4.4 Gy/GBq, p = 0.04, respectively). No significant differences in mean tumor and index lesion doses were observed between responders and non-responders according to RECIST 1.1, PSMA-TV, and biochemical response criteria. CONCLUSION: Compared to mean tumor doses on a patient level, single index-lesion-based SPECT dosimetry correlates equally well with the response to PSMA-RLT according to PERCIST criteria and may represent a fast and feasible dosimetry approach for clinical routine.
BACKGROUND: Dosimetry can tailor prostate-specific membrane-antigen-targeted radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However, whole-body tumor dosimetry is challenging in patients with a high tumor burden. We evaluate a simplified index-lesion-based single-photon emission computed tomography (SPECT) dosimetry method in correlation with clinical outcome. METHODS: 30 mCRPC patients were included (median 71 years). The dosimetry was performed for the first cycle using quantitative 177Lu-SPECT. The response was evaluated using RECIST 1.1 and PERCIST criteria, as well as changes in PSMA-positive tumor volume (PSMA-TV) in post-therapy PSMA-PET and biochemical response according to PSA changes after two RLT cycles. RESULTS: Mean tumor doses as well as index-lesion doses were significantly higher in PERCIST responders compared to non-responders (10.2 ± 12.0 Gy/GBq vs. 4.0 ± 2.9 Gy/GBq, p = 0.03 and 13.7 ± 14.2 Gy/GBq vs. 5.9 ± 4.4 Gy/GBq, p = 0.04, respectively). No significant differences in mean tumor and index lesion doses were observed between responders and non-responders according to RECIST 1.1, PSMA-TV, and biochemical response criteria. CONCLUSION: Compared to mean tumor doses on a patient level, single index-lesion-based SPECT dosimetry correlates equally well with the response to PSMA-RLT according to PERCIST criteria and may represent a fast and feasible dosimetry approach for clinical routine.
Authors: Alexander Heinzel; Dima Boghos; Felix M Mottaghy; Florian Gaertner; Markus Essler; Dirk von Mallek; Hojjat Ahmadzadehfar Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-29 Impact factor: 9.236
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Thomas W Barber; Aviral Singh; Harshad R Kulkarni; Karin Niepsch; Baki Billah; Richard P Baum Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057
Authors: Bernhard Grubmüller; Daniela Senn; Gero Kramer; Pascal Baltzer; David D'Andrea; Karl Hermann Grubmüller; Markus Mitterhauser; Harald Eidherr; Alexander R Haug; Wolfgang Wadsak; Sarah Pfaff; Shahrokh F Shariat; Marcus Hacker; Markus Hartenbach Journal: Eur J Nucl Med Mol Imaging Date: 2018-12-19 Impact factor: 9.236
Authors: Maximilian A Kirchner; Adrien Holzgreve; Matthias Brendel; Michael Orth; Viktoria C Ruf; Katja Steiger; Dennis Pötter; Lukas Gold; Marcus Unterrainer; Lena M Mittlmeier; Enio Barci; Roland E Kälin; Rainer Glass; Simon Lindner; Lena Kaiser; Jessica Maas; Louisa von Baumgarten; Harun Ilhan; Claus Belka; Johannes Notni; Peter Bartenstein; Kirsten Lauber; Nathalie L Albert Journal: Front Oncol Date: 2021-11-17 Impact factor: 6.244
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Lilja B Solnes; Steven P Rowe Journal: Prostate Date: 2022-03-14 Impact factor: 4.012